Literature DB >> 11564773

Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome.

J Ø Bohnhorst1, M B Bjørgan, J E Thoen, J B Natvig, K M Thompson.   

Abstract

Analyses of B cells in the bone marrow and secondary lymphoid tissues have revealed a broad range of cell surface markers defining B cell subpopulations, but only a few of these have been used to analyze B cell subpopulations in peripheral blood (PB). We report here the delineation of circulating PB B cell subpopulations by staining for CD19, CD38, and IgD in combination with CD10, CD44, CD77, CD95, CD23, IgM, and the B cell memory marker CD27. The utility of this approach is shown by the demonstration of disturbances of circulating B cell subpopulations in patients with autoimmune disease. Five mature B cell (Bm) subpopulations were identified in normal PB that were comparable with the tonsillar Bm1, Bm2, early Bm5, Bm5 subpopulations and, surprisingly, to the germinal center (GC) founder cell subpopulation (Bm2' and Bm3delta-4delta), suggesting that some GC founder cells are circulating. No PB B cells resembled the Bm3 and Bm4 GC cells. Remarkably, some cells with the CD38-IgD+ phenotype, previously known as naive Bm1 cells, expressed CD27. The CD38-IgD+ subpopulation therefore includes both naive Bm1 cells and IgD+ memory B cells. This new classification of B cell developmental stages reveals disturbances in the proportions of B cell subpopulations in primary Sjögren's syndrome (pSS) patients compared with healthy donors and rheumatoid arthritis patients. Patients with pSS contained a significantly higher percentage of B cells in two activated stages, which might reflect a disturbance in B cell trafficking and/or alteration in B cell differentiation. These findings could be of diagnostic significance for pSS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564773     DOI: 10.4049/jimmunol.167.7.3610

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  124 in total

Review 1.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  K Szabó; G Papp; A Szántó; T Tarr; M Zeher
Journal:  Clin Exp Immunol       Date:  2015-10-21       Impact factor: 4.330

3.  A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation.

Authors:  Anne Månsson; Mikael Adner; Ulf Höckerfelt; Lars-Olaf Cardell
Journal:  Immunology       Date:  2006-06-16       Impact factor: 7.397

4.  Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  Jérémie Sellam; Corinne Miceli-Richard; Jacques-Eric Gottenberg; Marc Ittah; Frédéric Lavie; Christine Lacabaratz; Nicolas Gestermann; Alexis Proust; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

Review 5.  A conspicuous role for B cells In Sjögren's syndrome.

Authors:  Pierre Youinou; Valérie Devauchelle; Pascal Hutin; Rozenn Le Berre; Alain Saraux; Jacques-Olivier Pers
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 6.  Phenotypic and functional heterogeneity of human memory B cells.

Authors:  Iñaki Sanz; Chungwen Wei; F Eun-Hyung Lee; Jennifer Anolik
Journal:  Semin Immunol       Date:  2008-02-06       Impact factor: 11.130

7.  Analysis of IgM antibody production and repertoire in a mouse model of Sjögren's syndrome.

Authors:  Jill M Kramer; Nichol E Holodick; Teresa C Vizconde; Indu Raman; Mei Yan; Quan-Zhen Li; Daniel P Gaile; Thomas L Rothstein
Journal:  J Leukoc Biol       Date:  2015-09-17       Impact factor: 4.962

8.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

9.  The inhibitory potential of Fc receptor homolog 4 on memory B cells.

Authors:  Gotz R A Ehrhardt; Randall S Davis; Joyce T Hsu; Chuen-Miin Leu; Annette Ehrhardt; Max D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

10.  Altered B Cell Homeostasis in Patients with Major Depressive Disorder and Normalization of CD5 Surface Expression on Regulatory B Cells in Treatment Responders.

Authors:  Diana Ahmetspahic; Kathrin Schwarte; Oliver Ambrée; Christian Bürger; Vladislava Falcone; Katharina Seiler; Mehrdad Rahbar Kooybaran; Laura Grosse; Fernand Roos; Julia Scheffer; Silke Jörgens; Katja Koelkebeck; Udo Dannlowski; Volker Arolt; Stefanie Scheu; Judith Alferink
Journal:  J Neuroimmune Pharmacol       Date:  2017-09-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.